We await with great interest studies examining the potential of AMPK inhibitors to treat established cancers, although the lack of truly specific inhibitors is a current impediment—we therefore also hope to see much more selective inhibitors emerging from the drug development pipelines. The gene discussed is PRKAA2; the disease is cancer.